Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 51
Filter
1.
Gut and Liver ; : 375-381, 2023.
Article in English | WPRIM | ID: wpr-1000380

ABSTRACT

Background/Aims@#Real-time polymerase chain reaction (RT-PCR) is a fast and simple method for the simultaneous detection of clarithromycin (CLR) resistance and Helicobacter pylori. We evaluated the effectiveness of RT-PCR compared to that of the rapid urease test (RUT) and assessed its value in verifying CLR resistance. @*Methods@#A total of 70 specimens with confirmed H. pylori infection in culture were enrolled and analyzed in this prospective study. All specimens were subjected to RT-PCR assay using fluorescence melting peak signals to detect H. pylori infection and CLR resistances caused by either A2142G or A2143G mutations in the 23S ribosomal RNA gene (23S rRNA). The results were compared to those of RUT and antimicrobial susceptibility culturing tests to investigate the efficacy of RT-PCR. @*Results@#Among the 70 specimens analyzed, the positivity rate was 97.1% (68/70) with RT-PCR and 82.9% (58/70) with RUT. CLR resistance (minimum inhibitory concentration >1.0 μg/mL) was confirmed in 18.6% (13/70), and fluorescence melting curve analysis showed that 84.6% (11/13) had point mutations in 23S rRNA. Ten specimens had only A2143G mutation, and one specimen contained both A2142G and A2143G mutations. @*Conclusions@#RT-PCR assay was found to be more efficient than RUT in detecting H. pylori infection and could effectively verify CLR resistance compared to the antimicrobial susceptibility culturing test. Considering the high sensitivity and accessibility of RT-PCR method, it could be used to easily detect CLR-resistant H. pylori, thus helping clinicians select suitable treatment regimen and improve the eradication rate.

2.
Journal of Korean Medical Science ; : e227-2022.
Article in English | WPRIM | ID: wpr-938061

ABSTRACT

Background@#The rapid urease test (RUT) is a major diagnostic tool for detecting Helicobacter pylori infection. This study aimed to establish an objective method for measuring the color changes in the RUT kit to improve the test’s diagnostic accuracy. @*Methods@#A UV-visible spectrophotometer was selected as the colorimeter; experiments were conducted in three stages to objectively identify the color changes in the RUT kit. @*Results@#First, the urea broth solution showed an identifiable color change from yellow to red as the pH increased by 0.2. The largest transmittance difference detected using the UV-visible spectrophotometer was observed at a 590-nm wavelength. Second, the commercialized RUT kit also showed a gradual color change according to the pH change detected using the UV-visible spectrophotometer. Third, 13 cases of negative RUT results with a biopsy specimen and 16 of positive RUT results were collected. The transmittance detected using the UV-visible spectrophotometer showed a clear division between the positive and negative RUT groups; the largest difference was observed at a 559-nm wavelength. The lowest transmittance in the negative RUT group was 64, while the highest in the positive RUT group was 56, at the 559-nm wavelength. The UV-visible spectrophotometry reading showed a consistency of 92.7% compared with that of manual reading. @*Conclusion@#A transmittance of 60 at a 559-nm wavelength detected using UV-visible spectrophotometer can be used as a cutoff value for interpreting RUT results; this will help develop an automatic RUT kit reader with a high accuracy.

3.
Gut and Liver ; : 535-546, 2022.
Article in English | WPRIM | ID: wpr-937603

ABSTRACT

Background/Aims@#We examined the efficacy and safety of tegoprazan as a part of first-line triple therapy for Helicobacter pylori eradication. @*Methods@#A randomized, double-blind, controlled, multicenter study was performed to evaluate whether tegoprazan (50 mg)-based triple therapy (TPZ) was noninferior to lansoprazole (30 mg)-based triple therapy (LPZ) (with amoxicillin 1 g and clarithromycin 500 mg; all administered twice daily for 7 days) for treating H. pylori. The primary endpoint was the H. pylori eradication rate. Subgroup analyses were performed according to the cytochrome P450 (CYP) 2C19 genotype, the minimum inhibitory concentration (MIC) of amoxicillin and clarithromycin, and underlying gastric diseases. @*Results@#In total, 350 H. pylori-positive patients were randomly allocated to the TPZ or LPZ group. The H. pylori eradication rates in the TPZ and LPZ groups were 62.86% (110/175) and 60.57% (106/175) in an intention-to-treat analysis and 69.33% (104/150) and 67.33% (101/150) in a per-protocol analysis (non-inferiority test, p=0.009 and p=0.013), respectively. Subgroup analyses according to MICs or CYP2C19 did not show remarkable differences in eradication rate. Both first-line triple therapies were well-tolerated with no notable differences. @*Conclusions@#TPZ is as effective as proton pump inhibitor-based triple therapy and is as safe as first-line H. pylori eradication therapy but does not overcome the clarithromycin resistance of H. pylori in Korea

4.
Gut and Liver ; : 228-236, 2016.
Article in English | WPRIM | ID: wpr-25626

ABSTRACT

BACKGROUND/AIMS: To identify the risk factors for metachronous gastric neoplasms in patients who underwent an endoscopic resection of a gastric neoplasm. METHODS: We prospectively collected clinicopathologic data and measured the methylation levels of HAND1, THBD, APC, and MOS in the gastric mucosa by methylation-specific real-time polymerase chain reaction in patients who underwent endoscopic resection of gastric neoplasms. RESULTS: A total of 257 patients with gastric neoplasms (113 low-grade dysplasias, 25 high-grade dysplasias, and 119 early gastric cancers) were enrolled. Metachronous gastric neoplasm developed in 7.4% of patients during a mean follow-up of 52 months. The 5-year cumulative incidence of metachronous gastric neoplasm was 4.8%. Multivariate analysis showed that moderate/severe corpus intestinal metaplasia and family history of gastric cancer were independent risk factors for metachronous gastric neoplasm development; the hazard ratios were 4.12 (95% confidence interval [CI], 1.23 to 13.87; p=0.022) and 3.52 (95% CI, 1.09 to 11.40; p=0.036), respectively. The methylation level of MOS was significantly elevated in patients with metachronous gastric neoplasms compared age- and sex-matched patients without metachronous gastric neoplasms (p=0.020). CONCLUSIONS: In patients who underwent endoscopic resection of gastric neoplasms, moderate/severe corpus intestinal metaplasia and a family history of gastric cancer were independent risk factors for metachronous gastric neoplasm, and MOS was significantly hypermethylated in patients with metachronous gastric neoplasms.


Subject(s)
Aged , Female , Humans , Male , Middle Aged , Basic Helix-Loop-Helix Transcription Factors/genetics , DNA Methylation , Gastrectomy/methods , Genes, APC/physiology , Genes, mos/genetics , Incidence , Multivariate Analysis , Neoplasms, Second Primary/epidemiology , Proportional Hazards Models , Risk Factors , Stomach Neoplasms/genetics , Thrombomodulin/genetics
5.
Intestinal Research ; : 20-33, 2014.
Article in English | WPRIM | ID: wpr-113282

ABSTRACT

Mucosal surface of the intestinal tract is continuously exposed to a large number of microorganisms. To manage the substantial microbial exposure, epithelial surfaces produce a diverse arsenal of antimicrobial proteins (AMPs) that directly kill or inhibit the growth of microorganisms. Thus, AMPs are important components of innate immunity in the gut mucosa. They are frequently expressed in response to colonic inflammation and infection. Expression of many AMPs, including human beta-defensin 2-4 and cathelicidin, is induced in response to invasion of pathogens or enteric microbiota into the mucosal barrier. In contrast, some AMPs, including human alpha-defensin 5-6 and human beta-defensin 1, are constitutively expressed without microbial contact or invasion. In addition, specific AMPs are reported to be associated with inflammatory bowel disease (IBD) due to altered expression of AMPs or development of autoantibodies against AMPs. The advanced knowledge for AMPs expression in IBD can lead to its potential use as biomarkers for disease activity. Although the administration of exogenous AMPs as therapeutic strategies against IBD is still at an early stage of development, augmented induction of endogenous AMPs may be another interesting future research direction for the protective and therapeutic purposes. This review discusses new advances in our understanding of how intestinal AMPs protect against pathogens and contribute to pathophysiology of IBD.


Subject(s)
Humans , Autoantibodies , Biomarkers , Colitis , Colon , Immunity, Innate , Inflammation , Inflammatory Bowel Diseases , Intestines , Microbiota , Mucous Membrane
6.
The Korean Journal of Gastroenterology ; : 191-205, 2013.
Article in Korean | WPRIM | ID: wpr-169737

ABSTRACT

A complex microbiota colonizes mucosal layers in different regions of the human gut. In the healthy state, the microbial communities provide nutrients and energy to the host via fermentation of non-digestible dietary components in the large intestine. In contrast, they can play roles in inflammation and infection, including gastrointestinal diseases and metabolic syndrome such as obesity. However, because of the complexity of the microbial community, the functional connections between the enteric microbiota and metabolism are less well understood. Nevertheless, major progress has been made in defining dominant bacterial species, community profiles, and systemic characteristics that produce stable microbiota beneficial to health, and in identifying their roles in enteric metabolism. Through studies in both mice and humans, we are recently in a better position to understand what effect the enteric microbiota has on the metabolism by improving energy yield from food and modulating dietary components. Achieving better knowledge of this information may provide insights into new possibilities that reconstitution of enteric microbiota via diet can provide the maintenance of healthy state and therapeutic/preventive strategies against metabolic syndrome such as obesity. This review focuses on enteric microbial composition and metabolism on healthy and diseased states.


Subject(s)
Animals , Humans , Bacteria/growth & development , Diet , Gastrointestinal Diseases/microbiology , Inflammation/microbiology , Intestines/microbiology , Metabolic Syndrome/microbiology , Microbiota , Probiotics
7.
Gut and Liver ; : 552-559, 2013.
Article in English | WPRIM | ID: wpr-103741

ABSTRACT

BACKGROUND/AIMS: Helicobacter pylori infection induces cyclooxygenase-2 (COX-2) and epidermal growth factor receptor (EGFR) overexpression, and these factors may engage in cross-talk. The aim of the present study was to evaluate the effect of H. pylori on EGFR signaling pathways and to determine whether celecoxib has an inhibitory effect on this pathway. METHODS: The AGS cell line was cocultured with H. pylori G27 and the isogenic cagE- mutant. The expression of COX-2, EGFR, heparin binding-epidermal growth factor (HB-EGF), and transforming growth factor-beta (TGF-beta) was measured by real time-polymerase chain reaction (RT-PCR). Next, Western blot analyses of COX-2, EGFR, total Akt, phosphorylated Akt (pAkt), and phosphorylated glycogen synthase kinase-3beta (pGSK3beta) were performed after incubating H. pylori-treated AGS cells for 24 hours with various concentrations of celecoxib (0, 10, 20, and 30 micromol/L). RESULTS: H. pylori infection upregulated the mRNA levels of COX-2, EGFR, HB-EGF, and TGF-beta, as detected by RT-PCR. However, AGS cells treated with cagE- mutants, which have a defective type IV secretion system, did not exhibit EGFR upregulation. Celecoxib had inhibitory effects on the H. pylori-induced overexpression of COX-2 (p=0.015), EGFR (p=0.025), pAkt (p=0.025), and pGSK3beta (p=0.029) by Western blot analysis. CONCLUSIONS: H. pylori with an intact type IV secretion system activated the COX-2 and EGFR-Akt pathways in the AGS cell line. As celecoxib exhibited inhibitory effects on the EGFR signaling pathway, the cross-talk of COX-2 and EGFR likely mediates H. pylori-induced gastric cancer.


Subject(s)
Blotting, Western , Cell Line , Cyclooxygenase 2 , Epidermal Growth Factor , Glycogen Synthase , Helicobacter , Helicobacter pylori , Heparin , Intercellular Signaling Peptides and Proteins , Pyrazoles , ErbB Receptors , RNA, Messenger , Signal Transduction , Stomach Neoplasms , Sulfonamides , Transforming Growth Factor beta , Up-Regulation
8.
The Korean Journal of Gastroenterology ; : 338-346, 2012.
Article in Korean | WPRIM | ID: wpr-33545

ABSTRACT

BACKGROUND/AIMS: In spite of the improvement of medical treatment for the peptic ulcer disease (PUD), PUD is still one of the common upper gastrointestinal diseases. The purpose of this study was to evaluate the risk factors and general characteristics of Korean patients diagnosed as PUD at a single third referral center. METHODS: A total of 310 patients, diagnosed as PUD through endoscopy during one year of 2007 at Seoul National University Bundang Hospital were, retrospectively, evaluated regarding age, gender, Helicobacter pylori (H. pylori) positivity, clinical manifestations, comorbidities and medications. In addition, PUD was analyzed in the aspect of ulcer location, type of visit, gastrointestinal bleeding, and age. RESULTS: The mean age was 61.5 years old (48.1% over 65) and 208 (66.7%) patients were men. The rate of H. pylori infection was 47.8%, and any ulcerogenic medication history such as antiplatelet agents and NSAIDs was found to be 21.0% (65 patients). The rate of idiopathic peptic ulcer without evidence of H. pylori and NSAIDs was found to be 40.6% (126 patients). Among 310 PUD patients, bleeding symptoms such as melena, hematemesis and hematochezia occurred in 110 patients (35.5%). CONCLUSIONS: PUD was more prevalent in the elderly patients and frequently associated with bleeding. Substantial proportion of PUD patients had neither H. pylori infection nor history of ulcerogenic medications, suggesting of increasing prevalence of idiopathic PUD.


Subject(s)
Adult , Aged , Aged, 80 and over , Female , Humans , Male , Middle Aged , Age Factors , Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Gastrointestinal Hemorrhage , Gastroscopy , Helicobacter Infections/complications , Helicobacter pylori , Hematemesis , Melena , Peptic Ulcer/diagnosis , Platelet Aggregation Inhibitors/therapeutic use , Prevalence , Referral and Consultation , Retrospective Studies , Risk Factors , Sex Factors
10.
The Korean Journal of Gastroenterology ; : 74-81, 2011.
Article in Korean | WPRIM | ID: wpr-182418

ABSTRACT

BACKGROUND/AIMS: This study was performed to evaluate whether the prevalence rates of primary antibiotic resistance in Helicobacter pylori (H. pylori) isolates and the eradication rate of H. pylori could be different between cancer and non-cancer patients. METHODS: H. pylori were isolated from gastric mucosal biopsy specimens obtained from 269 Koreans, who did not have any eradication therapy history and were diagnosed as one of the following diseases; chronic gastritis, benign gastric ulcer, duodenal ulcer or gastric cancer. The susceptibilities of the H. pylori isolates to amoxicillin, clarithromycin, metronidazole, tetracycline, azithromycin, ciprofloxacin, levofloxacin and moxifloxacin were examined with the agar dilution method. In addition, eradication rate of H. pylori was evaluated. RESULTS: There was no significant difference in the primary antibiotic resistance to above eight antibiotics among chronic gastritis, peptic ulcer disease and gastric cancer. Furthermore there was no difference of antibiotic resistance between cancer and non-cancer patients, and there was no difference of eradication rate of H. pylori according to disease. CONCLUSIONS: Primary antibiotic resistance and H. pylori eradication rate were not different between cancer and non-cancer patients.


Subject(s)
Adult , Aged , Female , Humans , Male , Middle Aged , 2-Pyridinylmethylsulfinylbenzimidazoles/therapeutic use , Amoxicillin/therapeutic use , Anti-Bacterial Agents/therapeutic use , Chronic Disease , Clarithromycin/therapeutic use , Drug Resistance, Bacterial , Drug Therapy, Combination , Duodenal Ulcer/complications , Gastritis/complications , Helicobacter Infections/drug therapy , Helicobacter pylori/drug effects , Microbial Sensitivity Tests , Omeprazole/therapeutic use , Peptic Ulcer/complications , Proton Pump Inhibitors/therapeutic use , Republic of Korea , Stomach Neoplasms/complications
11.
The Korean Journal of Gastroenterology ; : 300-310, 2011.
Article in Korean | WPRIM | ID: wpr-78290

ABSTRACT

Inflammatory bowel disease (IBD), the most important entities being ulcerative colitis and Crohn's disease, are chronic, relapsing and remitting inflammatory conditions that result from chronic dysregulation of the mucosal immune system in the intestinal tract. Although the precise pathogenesis of IBD is still incompletely understood, increased levels of proinflammatory cytokines, including interleukin (IL)-1beta, IL-18 and tumor necrosis factor-alpha, are detected in active IBD and correlate with the severity of inflammation, indicating that these cytokines may play a key role in the development of IBD. Recently, the intracellular nucleotide-binding oligomerization domain-like receptor (NLR) family members, including NLRP1, NLRP3, NLRC4 and NLRP6, are emerging as important regulators of intestinal homeostasis. Together, one of those aforementioned molecules or the DNA sensor absent in melanoma 2 (AIM2), apoptosis-associated speck-like protein containing 'a caspase recruitment domain (CARD)' (ASC) and caspase-1 form a large (>700 kDa) multi-protein complex called the inflammasome. Stimulation with specific microbial and endogenous molecules triggers inflammasome assembly and caspase-1 activation. Activated caspase-1 leads to the secretion of proinflammatory cytokines, including IL-1beta and IL-18, and the promotion of pyroptosis, a form of phagocyte cell death induced by bacterial pathogens, in an inflamed tissue. Therefore, inflammasomes are assumed to mediate host defense against microbial pathogens and gut homeostasis, so that their dysregulation might contribute to IBD pathogenesis. This review focuses on recent advances of the role of NLRP3 inflammasome signaling in IBD pathogenesis. Improving knowledge of the inflammasome could provide insights into potential therapeutic targets for patients with IBD.


Subject(s)
Humans , CARD Signaling Adaptor Proteins/metabolism , Carrier Proteins/metabolism , Caspase 1/metabolism , Inflammasomes/metabolism , Inflammatory Bowel Diseases/metabolism , Interleukin-18/metabolism , Interleukin-1beta/metabolism , Signal Transduction
12.
The Korean Journal of Gastroenterology ; : 221-229, 2011.
Article in Korean | WPRIM | ID: wpr-142692

ABSTRACT

BACKGROUND/AIMS: This study was performed to compare the prevalence rates of primary antibiotic resistance in Helicobacter pylori (H. pylori) isolates among different regions of Korea. METHODS: H. pylori were isolated from gastric mucosal biopsy specimens of 99 Koreans who lived in Gyeonggi (n=40), Kangwon province (n=40) and Busan (n=19) from April to August in 2008. All the patients had no history of H. pylori eradication therapy. The susceptibilities of the H. pylori isolates to amoxicillin, clarithromycin, metronidazole, tetracycline, azithromycin, ciprofloxacin, levofloxacin, and moxifloxacin were tested according to the agar dilution method. RESULTS: There was a difference in resistance to clarithromycin in three institutes located among Gyeonggi (32.5%), Kangwon province (12.5%) and Busan (42.1%) by One way ANOVA test (p=0.027) and nonparametric Kruskal Wallis test (p=0.027). However, by post-hoc analysis, there was no statistically significant difference among three regions. Similarly, the other 7 antibiotics (amoxicillin, metronidazole, tetracycline, azithromycin, ciprofloxacin, levofloxacin and moxifloxacin) did not show any significant difference. CONCLUSIONS: There was no significant regional difference of the primary antibiotic resistance of H. pylori. However, the included patient number might not be enough for this conclusion demanding further evaluations.


Subject(s)
Female , Humans , Male , Middle Aged , Amoxicillin/pharmacology , Anti-Bacterial Agents/pharmacology , Aza Compounds/pharmacology , Azithromycin/pharmacology , Ciprofloxacin/pharmacology , Clarithromycin/pharmacology , Drug Resistance, Bacterial , Helicobacter Infections/epidemiology , Helicobacter pylori/drug effects , Metronidazole/pharmacology , Microbial Sensitivity Tests , Ofloxacin/pharmacology , Quinolines/pharmacology , Republic of Korea/epidemiology , Tetracycline/pharmacology
13.
The Korean Journal of Gastroenterology ; : 221-229, 2011.
Article in Korean | WPRIM | ID: wpr-142689

ABSTRACT

BACKGROUND/AIMS: This study was performed to compare the prevalence rates of primary antibiotic resistance in Helicobacter pylori (H. pylori) isolates among different regions of Korea. METHODS: H. pylori were isolated from gastric mucosal biopsy specimens of 99 Koreans who lived in Gyeonggi (n=40), Kangwon province (n=40) and Busan (n=19) from April to August in 2008. All the patients had no history of H. pylori eradication therapy. The susceptibilities of the H. pylori isolates to amoxicillin, clarithromycin, metronidazole, tetracycline, azithromycin, ciprofloxacin, levofloxacin, and moxifloxacin were tested according to the agar dilution method. RESULTS: There was a difference in resistance to clarithromycin in three institutes located among Gyeonggi (32.5%), Kangwon province (12.5%) and Busan (42.1%) by One way ANOVA test (p=0.027) and nonparametric Kruskal Wallis test (p=0.027). However, by post-hoc analysis, there was no statistically significant difference among three regions. Similarly, the other 7 antibiotics (amoxicillin, metronidazole, tetracycline, azithromycin, ciprofloxacin, levofloxacin and moxifloxacin) did not show any significant difference. CONCLUSIONS: There was no significant regional difference of the primary antibiotic resistance of H. pylori. However, the included patient number might not be enough for this conclusion demanding further evaluations.


Subject(s)
Female , Humans , Male , Middle Aged , Amoxicillin/pharmacology , Anti-Bacterial Agents/pharmacology , Aza Compounds/pharmacology , Azithromycin/pharmacology , Ciprofloxacin/pharmacology , Clarithromycin/pharmacology , Drug Resistance, Bacterial , Helicobacter Infections/epidemiology , Helicobacter pylori/drug effects , Metronidazole/pharmacology , Microbial Sensitivity Tests , Ofloxacin/pharmacology , Quinolines/pharmacology , Republic of Korea/epidemiology , Tetracycline/pharmacology
15.
The Korean Journal of Gastroenterology ; : 4-18, 2010.
Article in Korean | WPRIM | ID: wpr-194408

ABSTRACT

Intestinal mucosal layers are colonized by a complex microbiota that provides beneficial effects under normal physiological conditions, but is capable of contributing to chronic inflammatory disease such as inflammatory bowel disease (IBD) in susceptible individuals. Studies have shown that the enteric microbiota may drive the development of the gut immune system and can induce immune homeostasis as well as contribute to the development of IBD although the precise etiology is still unknown. Therefore, intestinal microbes seem to play a key role in the disease pathogenesis. Especially, dysbiosis, which is a shift in the composition of enteric microbiota to a nonphysiologic composition, is associated with one or more defects in mucosal immune functions, including microbe recognition, barrier function, intercellular communication, and anti-microbial effector mechanisms. This review focuses on the impact of enteric microbiota on the development and perpetuation of IBD. In addition, interactions with enteric bacteria and mucosal cells, including intestinal epithelial cells, dendritic cells, and T cells, to induce immune responses at mucosal surfaces have been discussed in the point of IBD pathogenesis. Further extension of the knowledge of enteric microbiota may lead to insights on the pathogenesis and new therapeutic strategies for IBD.


Subject(s)
Humans , Bacterial Physiological Phenomena , Host-Pathogen Interactions , Inflammatory Bowel Diseases/microbiology , Intestinal Mucosa/immunology , Intestines/microbiology , T-Lymphocytes/immunology
16.
The Korean Journal of Gastroenterology ; : 131-140, 2009.
Article in Korean | WPRIM | ID: wpr-205444

ABSTRACT

The subcommittee on the Assessment of Korean Gastroenterology Research Achievements of the Korean Society of Gastroenterology (KSG) conducted a survey of SCI papers in the fields of gastroenterology to evaluate the current status of Korean gastroenterology research. A total of 4,260 papers were confirmed as gastroenterology papers published by researchers affiliated with Korean medical institutions during the 1974-2006 periods. Among those 4,260 papers, 2,373 papers were authored by the members of the KSG. The first Korean gastroenterology SCI paper was published in 1981 and the Korean SCI gastroenterology publication output dramatically increased since 1995. Sixty three institutions published SCI papers and 14 institutions published more than 100 SCI papers. Sixteen members of KSG published more than 20 SCI papers as reprint authors. Ninety percent of Korean gastroenterology papers was cited at least once. KSG member reprint author papers were cited an average of 4.1 times within 3 years after publication. Korean gastroenterology research achievements over the last 30 years show a remarkable growth in terms of quantity and quality. The KSG members have played central roles in these progresses, and it is anticipated that they will continue to do so in the future.


Subject(s)
Academies and Institutes , Achievement , Authorship , Bibliometrics , Biomedical Research/statistics & numerical data , Gastroenterology/statistics & numerical data , Korea , Periodicals as Topic/statistics & numerical data
17.
Hanyang Medical Reviews ; : 76-91, 2007.
Article in Korean | WPRIM | ID: wpr-174064

ABSTRACT

Although Helicobacter pylori is susceptible to many antibiotics in vitro, only a few antibiotics, including amoxicillin, clarithromycin, metronidazole, tetracycline, and fluoroquinolones, have been frequently used in vivo to cure the infection in Korea. However, the frequent use for treatment regimens incorporating a proton pump inhibitor (PPI) and a combination of two or more antibiotics has resulted in the development of antibiotic resistance against H. pylori, which is a growing problem. The frequencies of resistance to antibiotics have varied widely according to geographical regions and subgroups within study populations. In this review article the prevalence of antibiotic resistance in H. pylori isolated from Korean patients, molecular mechanisms of the resistance and methods to detect the resistance have been discussed.


Subject(s)
Humans , Amoxicillin , Anti-Bacterial Agents , Clarithromycin , Drug Resistance, Microbial , Fluoroquinolones , Helicobacter pylori , Helicobacter , Korea , Metronidazole , Prevalence , Proton Pumps , Tetracycline
18.
Gut and Liver ; : 40-48, 2007.
Article in English | WPRIM | ID: wpr-14558

ABSTRACT

BACKGROUND/AIMS: Interactions between H. pylori and gastric epithelial cells contribute to gastric inflammation and epithelial damage. This study was performed to evaluate the gene expression profile of AGS cells by adhesion of H. pylori. METHODS: Changes in AGS cell gene expression induced by co-culturing with H. pylori (G69a strain) (4, 12, 24, 48 hours) were monitored using oligonucleotide microarray. Real-time reverse transcription-polymerase chain reaction (RT-PCR) was performed for data validation by the Assay-on-Demand Gene Expression product method. RESULTS: A total of 270 (2.66%) and 19 genes (0.19%) were up-regulated in AGS cells by H. pylori adhesion. Gene ontology analysis showed that up-regulated genes were categorized into endolipidase activity (17 genes), receptor binding (17 genes), integrin binding (4 genes), and two down-regulated genes into GTP binding category. The expression levels of 20 up- and 5 down-regulated genes were quantified by real-time RT-PCR. Sixteen genes involving cytokine activity (IL8, IL1B, TNF), hydrolase activity (PTP4A1, ERCC1, CASP8, CASP7, ACIN1), VIP receptor activity (VIPR2), and neuropeptide Y receptor activity (GPR83) were confirmed to be up-regulated. Five genes, namely, ARF3, M17S2, DDB2, AWP1, and WTAP were confirmed to be down-regulated. CONCLUSIONS: Host genes are significantly changed by H. pylori adhesion, which might explain the gastroduodenal pathogenesis induced by H. pylori infection.


Subject(s)
Epithelial Cells , Gene Expression , Gene Ontology , Guanosine Triphosphate , Helicobacter pylori , Helicobacter , Inflammation , Oligonucleotide Array Sequence Analysis , Receptors, Neuropeptide Y , Receptors, Vasoactive Intestinal Peptide , Transcriptome
19.
The Korean Journal of Gastroenterology ; : 337-349, 2006.
Article in Korean | WPRIM | ID: wpr-56756

ABSTRACT

The distribution of minimal inhibitory concentrations (MIC) for amoxicillin, clarithromycin, metronidazole, tetracycline, azithromycin, and fluoroquinolone (ciprofloxacin, levofloxacin, and moxifloxacin) have shifted to higher concentrations from 1987 to 2003 in Helicobacter pylori (H. pylori) strains isolated from Korean patients. MIC values of secondary isolates were higher than those of primary isolates. Of treatment-failure patients, 16.4% showed mixed infections with both antibiotic-susceptible and -resistant H. pylori strains. A total of 89.6% of patients with treatment failure and 52.3% of patients without antibiotic treatment had H. pylori strains resistant to two or more antimicrobial agents (multi-drug resistance, MDR). The most common antibiotics showing MDR were clarithromycin, metronidazole, and azithromycin. The resistance rates to both amoxicillin and clarithromycin were 34.3% in secondary isolates and 6.2% in primary isolates. The resistance rates to both clarithromycin and metronidazole were 73.1% in secondary isolates and 7.7% in primary isolates. In addition, there was a significant difference in antibiotic resistance between two institutions located at Seoul and Gyeonggi provinces. To provide adequate informations about susceptible antibiotics to clinicians, continuous surveillance of antibiotic susceptibilities is needed in Korea.


Subject(s)
Humans , Drug Resistance, Bacterial , Drug Resistance, Multiple, Bacterial , Helicobacter pylori/drug effects , Korea , Microbial Sensitivity Tests
20.
The Korean Journal of Gastroenterology ; : 156-161, 2006.
Article in Korean | WPRIM | ID: wpr-50303

ABSTRACT

BACKGROUND/AIMS: The prevalence of antibiotic resistance in Helicobacter pylori (H. pylori) infection has been reported to be increasing. However, the recent trend of eradication rates of H. pylori using first-line triple regimens has been rarely issued. Therefore, we aimed to determine the trend of H. pylori eradication rates in single center for recent eight years. METHODS: From January 1998 through October 2005, H. pylori eradication rates in 525 patients with H. pylori-positive peptic ulcer disease who received one-week triple regimens were retrospectively evaluated according to years, regimens, and ulcer locations. RESULTS: The overall H. pylori eradication rate was 78.7%. Yearly eradication rates from the year 1998 to 2005 were 83.7%, 80.4%, 81.4%, 78.8%, 75.3%, 77.6%, 78.9% and 77.6% consecutively by per-protocol analysis, However, no definite evidence of decreasing tendency of eradication rate was seen during the past eight years (p=0.419). Furthermore, there was no significant difference in the eradication rates according to the ulcer locations and regimens. CONCLUSIONS: Although it is found that there is no definite statistical evidence of decreasing trend for H. pylori eradication rate during past eight years, those for recent 5 years were lower than 80%, which suggests that we should scrutinize the trend of first-line H. pylori eradication rate, and concern for the expected lower rates in the near future.


Subject(s)
Adult , Aged , Aged, 80 and over , Female , Humans , Male , Middle Aged , Amoxicillin/therapeutic use , Anti-Bacterial Agents/therapeutic use , Clarithromycin/therapeutic use , Drug Therapy, Combination , Helicobacter Infections/drug therapy , Helicobacter pylori , Metronidazole/therapeutic use , Retrospective Studies , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL